, Tracking Stock Market Picks
Enter Symbol:
Autodesk, Inc. (ADSK) [hlAlert]

up 39.19 %

Autodesk, Inc. (ADSK) upgraded to Buy with price target $38 by Brigantine

Posted on: Wednesday,  Nov 16, 2011  9:25 AM ET by Brigantine

Brigantine rated Buy Autodesk, Inc. (NASDAQ: ADSK) on 11/16/2011, when the stock price was $35.92. Since
then, Autodesk, Inc. has gained 39.20% as of 11/20/2015's recent price of $50.00.
If you would have followed this Brigantine's recommendation on ADSK, you would have gained 39.19% of your investment in 1465 days.

Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson?s disease, and ACP-104 and ACP-103, both for the treatment of schizophrenia.

Brigantine Advisors is an integrated research team with its first focus on the technology sector. The equity research analysts on our team began their careers in industry with most spending an average of 7 years in their respective sectors. In addition, each analyst has spent over 10 plus years on Wall Street and collectively they have over 100 years of experience. We provide our investment clients timely analysis of market trends by identifying major technology shifts. Within the macro environment, we identify profitable investment opportunities with a focus on both the financial and technical capabilities of the companies we analyze.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/16/2011 9:25 AM Buy
35.92 38.00
as of 12/30/2011
1 Week down  -1.55 %
1 Month down  -10.97 %
3 Months down  -15.56 %
1 YTD down  -15.56 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/17/2010 12:25 PM Hold

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy